Brief: CRISPR Says European Commission Approves First Crispr/Cas9 Gene-Edited Therapy, Casgevy For Treatment Of Sickle Cell Disease & Transfusion-Dependent Beta Thalassemia

Crispr Therapeutics AG

13/02/2024 07:34

Feb 13 (Reuters) - CRISPR Therapeutics AG  CRSP.BN :
    * EUROPEAN COMMISSION APPROVES FIRST CRISPR/CAS9 GENE-EDITED
THERAPY, CASGEVY™ (EXAGAMGLOGENE AUTOTEMCEL), FOR THE TREATMENT
OF SICKLE CELL DISEASE (SCD) AND TRANSFUSION-DEPENDENT BETA
THALASSEMIA (TDT)

Source text for Eikon:  ID:nGNX50Ylnz 
Further company coverage:  CRSP.BN 

 ((Reuters.Briefs@thomsonreuters.com;))